top of page

Nabriva Therapeutics

“The secret to investing is to figure out the value of something – and then pay a lot less.”

- Joel Greenblatt

The Portfolio

The portfolio is up about +1.00% so far this year

Our benchmark index, the S&P 500 is up about +0.25% YTD.

If you're interested in the stock market, are looking for diversification or growth please feel free to connect me. I'm always available to talk, maybe provide some new ideas or to present to your group.

The 2020 Portfolio

I'm very happy with our investments this year, in particular some of the new buys. Northrop Grumman, Uber, Chipotle and Facebook have all been working hard for the portfolio. Northrop Grumman was an existing holding from last year. I added 7 shares at $344 and today it's trading around $373 against our cost basis of $312.77.

2020 will be another year of market volatility filled with surprises, sadness, joy and thrilling accomplishments in art, science, music, engineering, finance and I hope, advancement of the human condition. As individual investors we will not hide, fear or chase anything with euphoria. I hope that together we will work to understand not fear. We'll learn to think more and follow less. We will espouse our own ideas free of manufactured ones.

Today's BUYs

  • Nabriva (NBRV): Bought 6,500 @ $1.25

  • ​This is an existing holding that I'm happy adding to at lower prices. Today Nabriva declined to its 52-week low of $1.25/share. Nabriva is based in Dublin Ireland and has its U.S. headquarters in King of Prussia. Nabriva is developing CONTEPO, a drug that has the potential to be an important new treatment option for patients with complicated urinary tract infections caused by Gram-negative pathogens. In April the FDA rejected Nabriva's application but did not request any new data from patient trials or indicate any safety or efficacy concerns. The FDA's sole area of concern seems to be focused on a third party manufacturing partner. Nabriva has also sold institutional investors 13.8 million ordinary shares and warrants to purchase up to an aggregate of another 13.8 million. The share and accompanying warrants are being sold together at a combined purchase price of $1.45. The warrants have an exercise price of $1.90 per share and can be exercised six months following the date they are issued. They will expire on the three-year anniversary of the initial exercise date.

  • After today's purchase the portfolio holds 10,000 shares of Nabriva with an average cost of $1.57

"Markets don't go to zero, Portfolio's do.

Buy quality, be patient...and look twice for motorcycles."

- Clay Baker

Stay Invested,

Clay Baker


Keep Me Honest 2019

  1. S&P 500 declines to 2,350 or more (1-3-2019)

  2. Healthcare and Biotech sectors outperform (1-3-2019)

  3. S&P reaches 3,000 by year end (1-11-2019)

  4. CSCO reaches $60/share (1-18-2019)

  5. VEEV reaches $145/share (2-14-2019) (achieved $145.23 on 5-10-2019)

  6. CVS reaches $91.50 (2-27-2019)

  7. Bull market takes another leg up (4-7-2019)

  8. The Fed will lower rates 1-2 times (5-13-2019)

Clay's Rules

Rule #1: Don't lose money

Rule #2: See Rule #1

Rule #3: Portfolios go to zero, markets don't, Stay Invested

Rule #4: When a good stock you own drops 10% below your cost basis, add shares

Rule #5: Bull markets aren't sustained without the Transports

Rule #6: When Forward P/E is lower than TTM P/E, expect earnings to increase

Rule #7: When an investment bank sells below book value, buy it

Rule #8: Tips are for waiters. Do your own homework.

Rule #9: Don't sell a stock because you're bored with it. Do your own homework.

Disclosure: I am personally invested long in some or all of these stocks or funds that appear in the Stay Invested portfolio and may purchase or sell shares within the next 72 hours. I am also invested in other stocks and funds that do not appear in the Stay Invested portfolio but may be mentioned or related to this article. It is not my intention to advise or encourage the purchase or sale of any security. I am invested long in these securities mentioned in this post:


I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. This article is not intended to offer investing advice, guarantee 100% accurate predictions, or to be interpreted as providing a personal recommendation.

Featured Posts
Recent Posts
Search By Tags
Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square
bottom of page